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2 
Highlights 29 
x We have constructed improved antibiotic-resistance cassettes and suicide vectors for 30 
use in members of the Burkholderia cepacia complex (Bcc) and related species.  31 
x These vectors facilitate construction of mutants by gene disruption with antibiotic-32 
resistance markers. 33 
x We have validated the utility of the vectors for marked genetic inactivation in B. 34 
cenocepacia, B. lata and B. thailandensis. 35 
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Abstract 41 
To elucidate the function of a gene in bacteria it is vital that targeted gene 42 
inactivation (allelic replacement) can be achieved. Allelic replacement is often carried out by 43 
disruption of the gene of interest by insertion of an antibiotic-resistance marker followed by 44 
subsequent transfer of the mutant allele to the genome of the host organism in place of the 45 
wild-type gene. However, due to their intrinsic resistance to many antibiotics only selected 46 
antibiotic-resistance markers can be used in members of the genus Burkholderia, including 47 
the Burkholderia cepacia complex (Bcc). Here we describe the construction of improved 48 
antibiotic-resistance cassettes that specify resistance to kanamycin, chloramphenicol or 49 
trimethoprim effectively in the Bcc and related species. These were then used in 50 
combination with and/or to construct a series enhanced suicide vectors, pSHAFT2, 51 
pSHAFT3 and pSHAFT-GFP to facilitate effective allelic replacement in the Bcc. Validation 52 
of these improved suicide vectors was demonstrated by the genetic inactivation of selected 53 
genes in the Bcc species Burkholderia cenocepacia and B. lata, and in the non-Bcc species, 54 
B. thailandensis.  55 
 56 
3 
1. Introduction  57 
Burkholderia cepacia complex (Bcc) are a group of at least twenty closely related 58 
Gram-negative bacterial species of the Burkholderia genus, which are phenotypically similar 59 
but genetically different (Vandamme et al., 1997; De Smet et al., 2015). These species are 60 
found ubiquitously in the environment, including soil, water and the rhizosphere of some 61 
plants (Coenye and Vandamme, 2003). Many Bcc species have also been isolated from the 62 
sputum of cystic-fibrosis (CF) patients, identifying them as opportunistic pathogens of those 63 
with lung disease and weakened immune systems (Henry et al., 1997; Speert et al., 2002). 64 
Colonisation of the lungs by Bcc can result in several clinical outcomes, including chronic-65 
infection with gradual lung deterioration and a rare adverse reaction known as Cepacia 66 
syndrome, which leads to rapid lung decline, septicaemia, necrotizing pneumonia and is 67 
often fatal (Isles et al., 1984). The most prevalent causative agents of Bcc infections in CF-68 
patients in the UK, Canada and USA are B. cenocepacia and B. multivorans (Drevinek and 69 
Mahenthiralingam, 2010; De Soyza et al., 2010; Zlosnik et al., 2015). Unfortunately, Bcc 70 
infections can be difficult to treat due to the high intrinsic resistance of these bacteria to 71 
many antibiotics. Over recent years restrictions have been placed on individuals colonized 72 
with Bcc to prevent transmission of Bcc infections, by limiting their contact with at risk 73 
members of the population (Ledson et al., 1998).  74 
Efforts have been made to understand the virulence mechanisms used by Bcc 75 
bacteria that allow them to be successful pathogens. These include mechanisms of bacterial 76 
cell invasion, intracellular survival, quorum sensing, iron acquisition, and protein secretion 77 
(Martin and Mohr, 2000; Sokol et al., 2003; Visser et al., 2004; Mullen et al., 2007; Aubert et 78 
al., 2008; Uehlinger et al., 2009; Somvanshi et al., 2010). A key factor to aid in the 79 
characterization of these traits is the ability to manipulate the genome of Bcc species. 80 
Methods for targeted gene inactivation in Burkholderia have largely relied on the disruption 81 
of the target chromosomal gene with an antibiotic-resistance marker, either through 82 
employing an integrative vector (Flannagan et al., 2007; Chapalain et al., 2013) or by allelic 83 
replacement whereby the wild type gene is replaced by a copy of the target gene that is 84 
inactivated with an antibiotic-resistance cassette (Huber et al., 2001; Malott et al., 2005; 85 
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Agnoli et al., 2006). In the latter, two recombination crossover events are selected for (one 86 
occurring either side of the lesion in the target gene) and no vector sequences remain on the 87 
chromosome in the mutant. Vectors for generation of such marked mutants include plasmids 88 
in the pEX18 and pEX19 series (Hoang et al., 1998), and a vector constructed in our lab, 89 
pSHAFT (Agnoli et al. 2006).  90 
Due to their high level of intrinsic resistance to many antibiotics, the number of 91 
commonly employed resistance markers that can be used for genetic manipulation of Bcc 92 
species is generally restricted to those specifying increased resistance to trimethoprim, 93 
chloramphenicol and tetracycline. All three markers can be selected for in single copy in B. 94 
cenocepacia (Farmer and Thomas, 2004; Asghar et al., 2011; Ryan et al., 2013). For 95 
aminoglycoside-sensitive strains, whether naturally occurring (such as B. cenocepacia strain 96 
H111) or engineered, the aac and aph markers, which specify resistance to the 97 
aminoglycosides gentamycin and kanamycin, respectively, are selectable in single copy and 98 
can therefore also be used in allelic replacement experiments (Huber et al., 2001; Hamad et 99 
al., 2010; Inhülsen et al., 2012; Carlier et al., 2014).  100 
Allelic replacement in bacteria involving disruption of a target gene with a selectable 101 
resistance marker can be problematic if the host bacterium already exhibits a high degree of 102 
intrinsic resistance to the antibiotic, thereby precluding selection of the marker. This can be 103 
ameliorated if the antibiotic-resistance gene is efficiently expressed. However, the use of 104 
strong promoters to drive high-level transcription of the marker gene can exert detrimental 105 
polar effects that include destabilisation of plasmids housing such markers or unwanted or 106 
toxic expression of downstream genes following insertion of the marker in the host genome 107 
(Stueber and Bujard, 1982; Stassi and Lacks, 1982; Schrecke et al., 2013; our published 108 
observations). In these situations the negative effects of very active promoters can be 109 
circumvented by placement of a strong transcription terminator downstream of the selectable 110 
marker gene (Gentz et al., 1981; Fellay et al., 1987). Here we describe the construction of 111 
novel antibiotic-resistance cassettes where we have employed these principles either to 112 
increase expression of the antibiotic-resistance marker to facilitate its selection in a single 113 
copy or to prevent detrimental polar effects by blocking transcriptional readthrough into 114 
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downstream genes. These cassettes were used to build improved suicide vectors derived 115 
from the vector pSHAFT and were also used in conjunction with these vectors for allelic 116 
replacement in the Bcc and other members of the genus Burkholderia. 117 
 118 
2. Materials and methods 119 
2.1. Strains, plasmids, and growth conditions 120 
The bacterial strains and plasmids used in this study are given in supplementary 121 
Table S1. For cultivation of bacteria, strains were routinely grown in/on LB medium at 37oC. 122 
For selection of trimethoprim resistance in E. coli iso-sensitest agar (Oxoid) was employed, 123 
whereas for B. cenocepacia M9-minimal salts agar containing 0.5% glucose was used 124 
(except where indicated). M9-minimal salts used here contained 42 mM Na2HPO4, 22 mM 125 
KH2PO4, 19 mM NH4Cl, 9 mM NaCl, 1 mM MgSO4 and 100 ȝ0 &D&O2. For selection of 126 
kanamycin resistance in B. cenocepacia Lennox agar was utilised.  Antibiotics were used, 127 
when appropriate, at the following concentrations for selection of plasmids and antibiotic-128 
resistance cassettes in E. coli and Burkholderia species, as indicated: ampicillin, 100 ȝg/mL 129 
(E. coli); kanamycin, 50 ȝg/mL (E. coli and B. cenocepacia); chloramphenicol, 25 ȝg/mL (E. 130 
coli) and 50 ȝg/mL (B. cenocepacia); trimethoprim, 25 ȝg/mL (E. coli, B. cenocepacia and B. 131 
lata) and 50 ȝg/mL (B. thailandensis). For B. cenocepacia strains exhibiting a high intrinsic 132 
resistance to trimethoprim, such as K56-2, this antibiotic was included in the medium at 100 133 
ȝg/mL. 134 
 135 
2.2. DNA preparation and manipulation 136 
Recombinant DNA techniques were performed essentially as described in Sambrook 137 
et al. (1989). DNA amplification by PCR was performed as standard according to the 138 
manufacturer¶s instructions using KOD DNA polymerase enzyme (Millipore) and a G-storm 139 
thermocycler. Primers used in this study are indicated in supplementary Table S2, and were 140 
purchased from Eurogentec, Belgium. To extract DNA for PCR, bacterial colonies were 141 
resuspended in 200 ȝL TE buffer (10 mM Tris, 1.0 mM EDTA (pH 8.0)), boiled for 7 minutes, 142 
and then centrifuged to pellet cell debris. The supernatant was retained for use in PCR 143 
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(referred to as µboiled lysate¶). PCR products were purified from solution or by agarose gel-144 
extraction using a QIAquick PCR purification kit (Qiagen). DNA restriction enzymes were 145 
purchased from Promega or New England Biolabs. DNA was ligated using T4 DNA ligase 146 
(Promega). ¶ '1$ RYHUKDQJV ZHUH ILOOHG-in using DNA I polymerase Klenow fragment 147 
(Promega). Sequencing was performed by the Core Genomic Facility at The University of 148 
Sheffield, UK.  149 
 150 
2.3. Plasmid constructions  151 
Plasmids were extracted from saturated bacterial cultures using a spin-column-based 152 
plasmid mini-prep extraction kit (Thermo Scientific). Plasmids were transferred into E. coli by  153 
heat-shock assisted transformation according to Hanahan (1983). 154 
To construct p34E-Km, the Tn5-derived aphA2 gene, including its promoter 155 
(Rothstein and Reznikoff, 1981), was excised from pKNOCK-Km as a MluI fragment, end-156 
filled with DNA polymerase I Klenow fragment and ligated between the filled EcoRI sites of 157 
p34E-Tp.  158 
To generate p34E-Cm2, the catA2 gene of the plasmid pSHAFT was amplified with 159 
primers p34E-Cmfor2 and p34E-Cmrev, which incorporated a synthetic promoter (-10 and -160 
35 elements) upstream of the catA2 TIR in the amplified product. The 823 bp amplicon was 161 
restricted with EcoRI and used to replace the EcoRI-excised KmR cassette of p34E-Km. 162 
To construct p34E-TpTer, first a 306 bp DNA fragment containing the rrnB T1T2 163 
terminators was amplified from the plasmid pEA302T with rrnBterfor and rrnBterrev and 164 
restricted with BamHI and HindIII, following which it was ligated between the corresponding 165 
restriction sites of pUC18 to give pUC18Ter. Second, the megaprimer variation of SOE PCR 166 
(Perrin and Gilliland, 1990) was used to fuse the rrnB T1T2 terminators WR WKH ¶ end of 167 
dfrB2. To do this, the dfrB2 gene (and native promoter) was amplified from p34E-Tp with 168 
primer Tp(forward), DQGWKHIXVLRQSULPHU7SUHYHUVHWKDWZDVFRPSOHPHQWDU\WRWKH¶HQG169 
of the dfrB2 gene, including the stop FRGRQDQGFRQWDLQHGD¶WDLOZLWKESRIKRPRORJ\WR170 
the upstream region of the rrnB T1T2 DNA fragment. The resultant amplicon served as a 171 
forward megaprimer in combination with reverse primer rrn(R), to amplify a 903 bp dfrB2-172 
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rrnB T1BT2 fusion fragment from pUC18Ter. This product was then ligated between the 173 
EcoRI and HindIII sites of pUC19, giving rise to pUC19TpTer. Last, the TpTer cassette of 174 
pUC19TpTer was excised as a StuI fragment and ligated between the filled-in EcoRI sites of 175 
p34E-Km, thereby replacing the KmR cassette.  176 
To construct pSHAFT2, the catA2 region of pSHAFT was amplified with a pair of 177 
primers, pSHOOTERfor2 and pSHOOTERrev. The 871 bp product was digested with BamHI 178 
and SalI and ligated between the BglII and SalI sites of pSHAFT, thereby replacing the :-179 
Cm interposon.  180 
To construct pSHAFT3, first, a double-stranded oligonucleotide was generated by 181 
annealing oligonucleotides pSHAFT3MCSfor and pSHAFT3MCSrev. This was achieved by 182 
combining 45 PM of each oligonucleotide in 1x KOD DNA polymerase reaction buffer 183 
(Millipore) and 1 mM MgCl2, incubating at 90oC for 10 minutes followed by incubation at 184 
room temperature for 1 hour and subsequent purification of the double-stranded 185 
oligonucleotide. pSHAFT2 was restricted with NotI and EcoRI and ligated to the double-186 
stranded oligonucleotide, to generate pSHAFT3.  187 
To construct pSHAFT-GFP, an 866 bp DNA fragment containing the gfp coding 188 
sequence and Shine-Dalgarno was amplified from pBHR1-GFP with primers GFPfor and 189 
GFPrev, purified and digested with BamHI and SalI. This was then ligated between BglII-SalI 190 
sites of pSHAFT to replace the 3.7 kb :-Cm fragment of this vector. 191 
The sequences of p34E-Km, p34E-Cm2, p34E-TpTer, pSHAFT, pSHAFT2, 192 
pSHAFT3 and pSHAFT-GFP were deposited in GenBank database, and given the 193 
accession numbers KX485327, KX485328, KX485329, KX485330, KX485332, KX485333 194 
and KX485331, respectively. As we observed that the nucleotide sequence of the dfrB2 195 
cassette in p34E-Tp as deposited in the database is incorrect, we have also submitted an 196 
amended sequence of this plasmid that has been assigned accession number KX485326. 197 
pUC18Ter and pUC19TpTer were assigned accession numbers KX527623 and KX527624, 198 
respectively. 199 
 200 
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2.4. Gene replacement in B. cenocepacia 201 
To inactivate chromosomal genes in Burkholderia using pSHAFT2 or pSHAFT3, the 202 
antibiotic counter-selection-based strategy used for allelic replacement by pSHAFT was 203 
employed (Agnoli et al. 2006). For isolation of a B. cenocepacia BCAM0195::Tp mutant, a 204 
3.64 kb DNA fragment containing the BCAM0195 gene orthologue in strain H111 was 205 
amplified from a boiled lysate using primers BCAM0195for and BCAM0195rev, restricted 206 
with HindIII and BamHI and ligated between the corresponding sites of pBBR1MCS-1, 207 
generating pBBR1-%&$0¶ The cloned 3.11 kb gene fragment was then disrupted by 208 
ligation of the p34E-Tp-derived TpR cassette as a SmaI-fragment between two PmlI sites 209 
located 1.58 kb apart within BCAM0195, generating pBBR1-'%&$0¶7S7KH 2.04 kb 210 
'%&$0¶7S DOOHOH ZDV WUDQVIHUUHG WR S6+$)7 DV D XhoI-XbaI fragment to give 211 
pSHAFT2-'%&$0¶7S7KLVSODVPLGZDVconjugated into B. cenocepacia H111 using 212 
E. coli donor strain S17-1(ȜSLU) according to Herrero et al., (1990) and de Lorenzo and 213 
Timmis (1994), and B. cenocepacia exconjugants were selected on M9-glucose agar 214 
containing trimethoprim. Exconjugants were patched onto the same medium and also LB 215 
agar containing chloramphenicol. Exconjugants that were chloramphenicol-sensitive were 216 
identified as candidate 'BCAM0195::Tp mutants. Due to the loss of short regions of DNA at 217 
WKH ¶ DQG ¶ ends of BCAM0195 during the construction of pSHAFT2-'%&$0¶7S, 218 
potential 'BCAM0195::Tp mutants could be verified by PCR using the original 219 
BCAM0195for and BCAM0195rev primers, as they annealed to genomic sequences located 220 
a short distance either side of the region of DNA that was also present in pSHAFT2-221 
'%&$0¶7S.  222 
For isolation of a BCAL1709::TpTer mutant in B. cenocepacia AHA27, a 1.354 kb 223 
DNA fragment containing the ¶UHJLRQRI WKHBCAL1709 orthologue was amplified from B. 224 
cenocepacia Pc715j genomic DNA using primers BCAL1709for and BCAL1709rev, 225 
restricted with XbaI and XhoI, and the resulting 1.297 kb amplicon was ligated between the 226 
corresponding sites of pSHAFT-GFP to give rise to pSHAFT-GFP-BCAL1709. The 227 
BCAL1709 gene was then disrupted by ligation of the p34E-TpTer-derived TpR cassette as a 228 
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SmaI fragment into a unique ZraI site within BCAL1709, resulting in pSHAFT-GFP-229 
BCAL1709::TpTer. This plasmid was then conjugated into AHA27 and exconjugants 230 
containing the BCAL1709::TpTer allele within the genome were selected for as described for 231 
construction of the BCAM0195::Tp mutant. The presence of gfp on pSHAFT-GFP causes 232 
recipient colonies to fluoresce under UV light, and was used to distinguish between 233 
recombinants that arose through a single crossover (i.e. plasmid integration - fluorescent) 234 
and a double crossover (i.e. allelic replacement - non-fluorescent). 50 trimethoprim-resistant 235 
exconjugants were patched on duplicate IST agar plates containing trimethoprim. One of 236 
each pair of plates was exposed to UV light on a transilluminator in the dark to identify non-237 
fluorescent candidate AHA27 BCA1709::TpTer mutants. Candidate mutants from the non-238 
irradiated duplicate plate(s) were verified by PCR using primers BCAL1709forOut and 239 
BCAL1709revOut, which annealed to genomic sequences a short distance either side of the 240 
region of DNA that was also present in pSHAFT-GFP-BCAL1709::TpTer.  241 
 242 
3. Results and discussion  243 
3.1. Construction of antibiotic resistance cassettes for genetic manipulation of the 244 
Burkholderia cepacia complex 245 
To facilitate the generation of mutants in Burkholderia through insertional inactivation 246 
of chromosomal target genes by antibiotic resistance markers and the construction of useful 247 
plasmid vectors that would allow an investigation into gene function and control in members 248 
of this genus, we made derivatives of the cassette cloning vector, p34E (Tsang et al., 1991), 249 
harbouring the kanamycin- (aphA2), chloramphenicol- (catA2) and trimethoprim- (dfrB2), 250 
resistance genes. 251 
First, p34E-Km was constructed by replacing the trimethoprim-resistance (TpR) 252 
cassette of p34E-Tp with the Tn5-derived aphA2 (DSK¶-II) gene from pKNOCK-Km (Figure 253 
1). Although a similar kanamycin-resistance cassette (KmR) plasmid, p34S-Km (which 254 
contains the Tn903-derived DSK¶-Ia gene), has been previously described (Dennis and 255 
Zylstra, 1998a), the Tn5-derived antibiotic resistance marker in p34E-Km offers the 256 
advantage that it makes available the HindIII and SmaI sites flanking the cassette (as they 257 
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do not cut within the aphA2 gene) and also contains flanking EcoRI sites. Both types of 258 
cassette are of a similar size (~1.3 kb). A shorter variant of the Tn903-based KmR cassette 259 
lacking the internal HindIII and SmaI sites was subsequently constructed, but it lacks the 260 
flanking EcoRI sites and the possibility for directional cloning associated with p34E-Km 261 
(Dennis and Zylstra, 1998b). 262 
Most plasmids used for genetic manipulation that specify chloramphenicol resistance 263 
(CmR) harbour the Tn9-derived catA1 gene (or one that is closely related) that specifies an 264 
enzyme belonging to group 1 of the type A chloramphenicol acetyltransferases (CATs) 265 
(Shaw, 1983; Schwarz et al., 2004). A notable exception is mini-Tn5Cm, which contains the 266 
catA2 gene (de Lorenzo et al., 1990). Pertinently, chloramphenicol resistance conferred by 267 
this mini-transposon is selectable in single copy in B. cenocepacia (Farmer and Thomas, 268 
2004). However, the catA2 gene specifying this resistance is located on a large DNA 269 
fragment (the ~3.7 kb :-Cm interposon) that was used to assemble the transposon and is 270 
not available as a small cassette (Fellay et al., 1987; de Lorenzo et al., 1990). The :-Cm 271 
interposon includes a 2.8 kb DNA fragment derived from the cloning vector pKT210 which 272 
contains the 214 codon catA2 ORF and several other predicted ORFs found on the naturally 273 
occurring BHR plasmid pSa (Bagdasarian et al., 1981; Tait et al., 1982; Shaw, 1983; Fellay 274 
et al., 1987). In order to generate a compact CmR cassette containing an efficiently 275 
expressed cat gene, the catA2 gene contained on pSHAFT (a suicide plasmid derived from 276 
pUTmini-Tn5Cm (see below)), was modified to incorporate a synthetic V70-dependent 277 
promoter upstream of the catA2 TIR. The modified catA2 gene was used to replace the KmR 278 
cassette of p34E-Km, to generate p34E-Cm2 (Figure 1). The CmR cassette in p34E-Cm2, 279 
can be transferred to other vectors using any of the flanking restriction sites except SmaI 280 
(Figure 1), although even here, selection for chloramphenicol resistance would permit 281 
selection for the products of a tripartite ligation between the target vector and the two SmaI-282 
generated cassette fragments. As an alternative, either of the blunt end-generating SacI 283 
isoschizomers, Eco53kI or Ecl136II, may be used. 284 
The most similar vectors available as sources of a CmR cassette are p34S-Cm and -285 
Cm2 (Dennis and Zylstra, 1998a; 1998b). Rather than the catA2 gene present in p34E-Cm2, 286 
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these other plasmids contain the Tn9-derived catA1 gene and the cassettes are slightly 287 
longer (918 bp rather than 823 bp). p34S-Cm contains an internal EcoRI site whereas in 288 
p34S-Cm2 this site has been removed. However, unlike p34E-Cm2, p34S-Cm2 lacks 289 
flanking EcoRI sites. 290 
The trimethoprim-resistance gene (dfrB2) present on the cassette vectors p34E-Tp 291 
and p34S-Tp is under control of the very strong PcS integron promoter (also known as P1) 292 
(Lévesque et al., 1994; DeShazer and Woods, 1996; Dennis and Zylstra, 1998a; Jové et al., 293 
2010). We have observed that insertion of the TpR cassette in certain orientations in some 294 
plasmid vectors is not possible (see below) and when used in allelic replacement 295 
experiments it can result in impaired growth of the resultant mutants, presumably due to 296 
overexpression of chromosomal genes located downstream of the integrated cassette (S.S. 297 
and M.S.T., unpublished observations). To circumvent this problem, we modified the TpR 298 
cassette by placing the efficient T1T2 transcription terminators from the E. coli rrnB 299 
ribosomal RNA operon, downstream of the dfrB2 coding sequence (Brosius, 1984; Orosz et 300 
al., 1991). To do this, we started with pEA302T, a plasmid into which a 500 bp EcoRI 301 
fragment containing the 5S rRNA gene and the T1T2 terminators was cloned in order to 302 
prevent readthrough transcription of the tac promoter into the replication region (Amann et 303 
al., 1983). A DNA fragment containing only the rrnB T1T2 terminators was amplified using 304 
primers that also incorporated additional restriction sites at the flanking regions of the 305 
fragment, and was subsequently transferred to pUC18 to give pUC18Ter. 306 
The rrnB terminators (from pUC18Ter) were then fused to the dfrB2 gene (from 307 
p34E-Tp) by the megaprimer variation of the SOE PCR technique (Perrin and Gilliland, 308 
1990), and the amplicon was ligated into pUC19, giving rise to pUC19TpTer. Although the 309 
TpTer DNA fragment in pUC19TpTer can be transferred as a StuI or NdeI cassette, to 310 
increase its versatility, it was transferred into p34E-Km, substituting for the KmR cassette. 311 
The resultant plasmid, p34E-TpTer, is analogous to p34E-Tp but has strong transcription 312 
termination signals located downstream of the dfrB2 gene and includes the addition of NdeI 313 
sites in the flanking MCSs (Figure 1). 314 
 315 
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3.2. Construction of allelic replacement vectors, pSHAFT2 and pSHAFT3, for 316 
generation of marked mutants in the Burkholderia cepacia complex 317 
We sought to improve upon existing vectors used for allelic replacement in the Bcc. A 318 
useful vector for insertional inactivation of chromosomal genes with selective markers 319 
(usually antibiotic resistance cassettes) is pSHAFT, an R6K-based suicide plasmid (Figure 320 
2) (Agnoli et al., 2006). This vector was derived from the transposon delivery plasmid, 321 
pUTmini-Tn5Cm (de Lorenzo et al., 1990), by deletion of the tnp (transposase) gene and 322 
RQH RI WKH  ES UHSHDW VHTXHQFHV WKH µ, HQG¶ WKDW IODQN PLQL-Tn5Cm, and therefore it 323 
cannot be mobilised in the presence of transposase provided in trans. pSHAFT is also 324 
devoid of the pir gene, which specifies the plasmid replication initiator protein, S, and can 325 
therefore only replicate in bacteria containing the pir gene, such as E. coli CC118(Opir) 326 
(Herrero et al., 1990; Rakowski and Filutowicz, 2013). Along with the chloramphenicol-327 
resistance marker carried by mini-Tn5Cm, pSHAFT also contains the origin of transfer (oriT) 328 
from RP4 (RK2) that allows for efficient conjugal transfer of the plasmid to a variety of Gram-329 
negative bacterial species. Following transfer of a Bcc gene (or gene fragment) to pSHAFT, 330 
the gene is disrupted by insertion an antibiotic-resistance cassette (other than CmR) that is 331 
selectable in the Bcc. The plasmid is then introduced into a Bcc strain and selection for the 332 
presence of the antibiotic-resistance cassette (AbR) is applied. As the plasmid cannot 333 
replicate in Bcc, only recombinants are obtained in which the plasmid has recombined with 334 
the host genome at the locus that is homologous to the Bcc DNA present on the plasmid. 335 
This may result in integration of the plasmid into the genome (single crossover, CmR AbR) or 336 
allelic replacement (double crossover, CmS AbR). 337 
However, the major drawback with pSHAFT is the limited number of unique 338 
restriction sites that can be used for inserting mutant alleles for subsequent chromosomal 339 
targeting. One reason for this is the duplication of restriction sites either side of the CmR 340 
element during the assembly of mini-Tn5Cm in the progenitor plasmid pUT (de Lorenzo and 341 
Timmis, 1994). Moreover, as discussed above, the cassette specifying resistance to 342 
chloramphenicol is unnecessarily large, as mini-Tn5Cm was originally constructed by 343 
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inserting the ~3.7 kb :-Cm interposon between the 19 bp I and O ends of Tn5 carried by 344 
pUT (de Lorenzo et al., 1990).  345 
To improve the utility of pSHAFT, the vector was modified by replacing the 346 
interposon with a much shorter DNA fragment containing the catA2 gene under control of a 347 
synthetic V70-dependent promoter as also incorporated in p34E-Cm2, thereby decreasing 348 
the plasmid size from 7.5 to 4.6 kb. The new plasmid, pSHAFT2, contains 11 unique 349 
restriction sites located downstream of the catA2 gene, one of which (StuI) allows the 350 
cloning of blunt-ended fragments, while the BglII site can also accommodate BamHI-351 
generated fragments. At the catA2-distal end of the MCS are three closely spaced EcoRI 352 
sites that can be considered as an additional single unique site for cloning purposes (Figure 353 
2).  354 
The versatility of pSHAFT2 was then improved by replacing the region extending 355 
from the NotI site in the MCS to the most distant of the three EcoRI sites by a double-356 
stranded oligonucleotide that contained internal SpeI and ApaI sites. This also resulted in a 357 
net loss of two of the three EcoRI sites present in pSHAFT2 and removal of the mini-Tn5 O 358 
end that originated from the progenitor plasmid of pSHAFT. The new plasmid, pSHAFT3 359 
(4.5 kb), is shown in Figure 2. 360 
 361 
3.3. Construction of an allelic replacement vector, pSHAFT-GFP, that allows 362 
fluorogenic detection of integration events in the Burkholderia cepacia complex 363 
during generation of marked mutants 364 
To allow for inactivation of chromosomal genes where the Burkholderia strain already 365 
harbours a chloramphenicol resistance marker or to disrupt chromosomal genes with a CmR 366 
cassette we constructed pSHAFT-GFP (Figure 2).  This plasmid is analogous to pSHAFT2 367 
but with the catA2 gene replaced by the gfp gene, which therefore allows for fluorogenic 368 
detection of recombinants containing the genomically integrated vector. The forward primer 369 
used to amplify the gfp gene specified recognition sites for the restriction enzymes SalI, 370 
SmaI, BglII, XbaI, KpnI, XhoI and StuI and an artificial promoter containing the consensus -371 
35 and -10 elements for V70-dependent promoters, whereas the reverse primer specified 372 
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only a BamHI site. This vector is used in the same way as pSHAFT2 except for the fact that 373 
single and double crossover recombinants harbouring the selectable marker used to 374 
inactivate the target chromosomal gene are distinguished from each other by screening 375 
colonies for the absence of yellow-green fluorescence. Although this usually requires 376 
exposure to UV in the dark (a UV transilluminator works well in this regard), in some 377 
mutagenesis experiments the presence of the GFP marker can be discerned without 378 
recourse to UV exposure by the yellow-green colour of the colonies. 379 
 380 
3.4. Isolation of marked mutants in B. cenocepacia using the pSHAFT-vector series 381 
To inactivate chromosomal genes in Burkholderia using the pSHAFT-vector series, 382 
DNA fragments of t 1.0 kb containing the target gene (or gene fragment) are inserted into 383 
the MCS and then subsequently disrupted by insertion of an antibiotic resistance cassette 384 
(usually TpR, KmR or TcR) such that at least 0.5 kb of homology occurs between the cloned 385 
DNA target region and the chromosome either side of the lesion (Figure 3A). Depending on 386 
the availability of restriction sites, in some cases we have found it more convenient to first 387 
clone the target DNA sequence into a general-purpose plasmid vector and then introduce 388 
the antibiotic resistance cassette before transferring the disrupted DNA fragment to the 389 
suicide vector. In using these plasmids to inactivate chromosomal genes in Burkholderia, we 390 
have observed that the TpR cassette can often only be inserted into target genes in one 391 
orientation, such that transcription is directed towards the catA2 gene, and away from the 392 
origin of replication. We assume this is due to transcriptional destabilisation of plasmid 393 
replication functions (Gentz et al., 1981; Stueber and Bujard, 1982; Stassi and Lacks, 1982) 394 
as this problem does not occur with the TpTer cassette (our unpublished observations). 395 
Once the disrupted gene or gene fragment has been introduced into pSHAFT2, it is 396 
transferred to Burkholderia and selection is applied for the antibiotic resistance marker that 397 
was used to disrupt the gene or gene fragment present in the suicide vector, thus identifying 398 
strains that have integrated the disrupted allele into the genome by homologous 399 
recombination. Recombinants are of two types: those that are the result of a single 400 
crossover, in which the entire plasmid has integrated into the genome at the target gene 401 
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locus, and those that are the result of a double crossover in which only the mutant allele has 402 
been transferred to the genome in place of the original wild type gene (Figure 3A). In the 403 
former, wild type and mutated copies of the gene (or gene fragment) are present in the 404 
genome of the recipient bacterium, which will also specify increased resistance to 405 
FKORUDPSKHQLFRO GXH WR WKH LQWHJUDWHG YHFWRU 7KHVH DUH LGHQWLILHG E\ µSDWFKLQJ¶ RXW406 
recombinants on LB agar containing 50 Pg/ml chloramphenicol. Chloramphenicol-sensitive 407 
recombinants are screened for the presence of the mutated allele (and absence of the wild 408 
type allele) by PCR using primers that anneal to genomic sequences flanking the region that 409 
was originally cloned in the suicide vector. 410 
We have successfully used pSHAFT2 to generate several marked mutants within 411 
Bcc species. This included the insertional inactivation of the I35_0520 gene in B. 412 
cenocepacia strain H111 (the orthologue of BCAM0195 in strain J2315 and will be referred 413 
to as such hereon), which was disrupted by the TpR cassette derived from p34E-Tp. 414 
BCAM0195 is predicted to encode a non-ribosomal peptide synthetase (NRPS) of unknown 415 
function. During the isolation of the 'BCAM0195::Tp mutant, we observed that out of 50 416 
trimethoprim resistant exconjugants, 16 were chloramphenicol sensitive. Three of these 417 
were verified as 'BCAM0195::Tp mutants by PCR, where the DNA fragment amplified from 418 
BCAM0195 in the mutants was ~900 bp smaller than the wild-type, due to replacement of a 419 
large segment of BCAM0195 by the TpR cassette in the 'BCAM0195::Tp allele (Figure 3B). 420 
We have also used this plasmid to introduce an orbI::Tp allele into the genome of B. lata 421 
using the same selection conditions employed for allelic replacement in B. cenocepacia 422 
(results not shown). The applicability of the pSHAFT vectors to other non-Bcc species within 423 
the genus was established by generating a type VI secretion system mutant of B. 424 
thailandensis D PHPEHU RI WKH µSVHXGRPDOOHL¶ JURXS in an analogous fashion using 425 
pSHAFT3 as the vector and the TpTer cassette to disrupt the tssK gene (results not shown). 426 
To demonstrate the utility of pSHAFT-GFP it was used to inactivate the orthologue of 427 
the B. cenocepacia J2315 BCAL1709 gene that is present in the siderophore-negative B. 428 
cenocepacia mutant AHA27. AHA27 is a derivative of B. cenocepacia strain Pc715j that 429 
contains a mini-Tn5CmlacZYA insertion in the pobA gene encoding a phosphopantetheinyl 430 
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transferase (PPTase) required for activating NRPS enzymes, and thereby specifies higher 431 
levels of resistance to chloramphenicol than the parent strain (Asghar et al., 2011). Based 432 
on amino acid sequence alignment, BCAL1709 is very likely to encode a putative TonB-433 
dependent receptor thought to be involved in the uptake of an unknown xenosiderophore 434 
complexed with ferric iron (M.S.T., unpublished results). Following cloning of a BCAL1709 435 
gene fragment in pSHAFT-GFP and its disruption with the TpR cassette derived from p34E-436 
TpTer, the resultant plasmid (pSHAFT-GFP-BCAL1709::TpTer) was introduced into AHA27 437 
and candidate BCAL1709 mutants were selected by screening trimethoprim-resistant 438 
exconjugants for the absence of GFP-mediated fluorescence. Among 50 ex-conjugants that 439 
were screened in this way, 6 non-fluorescent recombinants were identified which were 440 
subsequently verified as BCAL1709 mutants by PCR, as indicated by a ~900 bp increase in 441 
the size of the DNA fragment amplified from the BCAL1709 locus due to the presence of the 442 
TpR cassette (Figure 3C). 443 
It should also be noted that use of the TpR cassette in allelic replacement 444 
experiments is also applicable to Burkholderia strains that exhibit higher levels of intrinsic 445 
resistance to trimethoprim, such as members of the B. cenocepacia ET-12 lineage, i.e. 446 
strains J2315 and K56-2. Due to the highly active promoter located upstream of the dfrB2 447 
ORF, expression of the gene is sufficiently strong to allow its selection in such strains by 448 
increasing the concentration of trimethoprim in the medium, and we have used pSHAFT2 to 449 
transfer TpR cassette-disrupted iron acquisition and type VI secretion system genes into 450 
K56-2 (unpublished results). 451 
 452 
4. Conclusion 453 
To conclude, we have constructed a series of versatile suicide vectors and antibiotic 454 
resistance cassettes that allow for the efficient and simple generation of marked mutants in 455 
Burkholderia species. We have improved upon our original vector pSHAFT by reducing the 456 
size of the CmR marker and increasing the availability of unique restriction site for cloning in 457 
vectors pSHAFT2 and pSHAFT3. The versatility of this plasmid series has been further 458 
enhanced by incorporating a fluorescent marker in pSHAFT-GFP to provide an alternative 459 
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means of distinguishing recombinants that have undergone allelic replacement events from 460 
those in which the suicide vector remains integrated in the genome. All vectors described 461 
here are a useful addition to the molecular toolkit required for the manipulation and 462 
subsequent characterisation of important genes in not only Burkholderia species, but 463 
potentially other Proteobacteria, such as enterobacteria and pseudomonads, where they 464 
may be used in combination with the antibiotic-resistance cassettes described herein or 465 
other available antibiotic-resistance markers.  466 
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Figure 1 Maps of novel antibiotic-cassette vectors. The location of antibiotic resistance-662 
conferring genes, bla (ampicillin-resistance), aphA2 (kanamycin-resistance), catA2 663 
(chloramphenicol-resistance) and dfrB2 (trimethoprim-resistance), and the plasmid ColE1 664 
origin of replication (oriR) are indicated for plasmids p34E-Km (top), p34E-Cm2 (left) and 665 
p34E-TpTer. Dual-cutting restriction sites that can be utilised to excise the antibiotic 666 
resistance cassette are also shown, as are internal sites that can be used for determination 667 
of the orientation of the cassette following insertion into a target gene. Restriction sites that 668 
occur only once in each plasmid are shown in bold. Note that additional sites for AseI, BsrGI, 669 
NheI and XmnI occur in the backbone of all three vectors that for clarity are not shown. 670 
Promoters for the cassette antibiotic-resistance genes are shown (Paph, Pcat, PcS). Maps 671 
created with SnapGene® software (from GSL Biotech; available at snapgene.com).  672 
 673 
Figure 2 Maps of the gene replacement vectors of the pSHAFT-series utilised for 674 
marked mutagenesis in Burkholderia. The location of antibiotic-resistance conferring 675 
genes, bla (ampicillin-resistance) and catA2 (chloramphenicol-resistance), RP4 origin of 676 
transfer (oriT), R6K origin of replication (oriR6K) and GFP-encoding gene (gfp) are indicated 677 
for pSHAFT, (left), pSHAFT2 (top right), pSHAFT3 (centre right) and pSHAFT-GFP (bottom 678 
right). The transcriptional orientation for each gene and restriction sites within the multiple 679 
cloning site of each vector are shown. Additional restriction sites in pSHAFT flanking :-Cm 680 
(dashed line) are also indicated. Restriction sites that occur only once in each plasmid are 681 
shown in bold. Maps created with SnapGene® software (from GSL Biotech; available at 682 
snapgene.com).  683 
 684 
Figure 3 Generation of marked mutants in B. cenocepacia using pSHAFT2 and 685 
pSHAFT-GFP derivatives. (A) t 1.0 kb of DNA containing the target gene (or gene 686 
fragment) is cloned into a pSHAFT vector and then disrupted by insertion of an antibiotic 687 
resistance cassette, ensuring there is at least 0.5 kb of homology between the cloned DNA 688 
target region and the chromosome on either side of the cassette. Following transfer of the 689 
pSHAFT-derived construct into Burkholderia, double crossover recombinants are selected 690 
25 
for based on their resistance to the antibiotic specified by the antibiotic resistance cassette, 691 
and either sensitivity to chloramphenicol (pSHAFT2 and pSHAFT3) or the absence of 692 
fluorescence (pSHAFT-GFP). Candidate mutants are then verified by PCR using primers 693 
that anneal to genomic sequences located either side of the region cloned into the allelic 694 
replacement vector µRXWVLGH¶SULPHUV LQGLFDWHGDV23IRUDQG23UHY. Drawn to scale. (B) 695 
PCR screening of candidate H111-'BCAM0195::Tp mutants following allelic replacement 696 
with pSHAFT2-'%&$0¶7S (C) PCR screening of candidate AHA27-BCAL1709::TpTer 697 
mutants following allelic replacement with pSHAFT-GFP-BCAL1709::TpTer.  698 
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Figure 1. 
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Supplemental 
Table S1. Bacterial strains and plasmids used in this study 
Strain or plasmid Genotype or description Source or reference 
 
E. coli strains 
  
JM83 Fí ara ǻ(lac-proAB) rpsL כ80dlacZǻM15 
(SmR) 
(Yanisch-Perron et al., 
1985) 
60ȜSLU thi-1 thr leu tonA lacY supE recA::RP4-2-
Tc::Mu (KmR)(Ȝpir) 
(Simon et al., 1983) 
S17-ȜSLU thi proA hsdR recA RP4-2-tet::Mu-1 
kan::Tn7 integrant (TpR, SmR) (Ȝpir) 
(Simon et al., 1983) 
   
B. cenocepacia strains 
 
Pc715j CF isolate, prototroph (McKevitt et al., 1989) 
H111 
J2315 
CF isolate, prototroph 
CF isolate 
(Römling et al., 1994) 
Holden et al., 2009 
K56-2 
 
 
AHA27 
CF isolate, prototroph 
 
 
Pc715j-pobA::mini-Tn5CmlacZYA 
Darling et al., 1998; 
Mahenthiralingam et 
al., 2000 
(Asghar et al., 2011) 
H111-
BCAM0195::Tp 
H111 with dfrB2 cassette inserted in 
BCAM0195 (TpR) 
This study 
AHA27-
BCAL1709::TpTer 
 
 
B. lata strains 
AHA27 with dfrB2 cassette containing rrnB 
T1T2 terminators inserted in BCAL1709 
(TpR) 
 
 
This study 
383 
 
Soil isolate, prototroph (also known as 
(ATCC 17760, NCIB 9087, LMG 22485) 
Stanier et al., 1966; 
Vanlaere et al., 2009 
30 
B. thailandensis 
strains 
E264 
 
Plasmids 
Rice paddy isolate, prototroph Brett et al.,1998 
pEA302T E. coli-specific vector containing phage Ȝ 
cI under Ptac with rrnB T1T2 terminators 
(ApR, TcR) 
(Amann et al., 1983) 
pBBR1MCS-1 Mobilizable BHR cloning vector, pBBR1-
replicon (CmR) 
(Kovach et al., 1994) 
pUC18 E. coli-specific cloning vector (ApR) (Yanisch-Perron et al., 
1985) 
pUC19 E. coli-specific cloning vector (ApR) (Yanisch-Perron et al., 
1985) 
pUC18Ter pUC18 containing rrnB T1T2 terminators 
(ApR) 
This study 
pUC19TpTer pUC19 containing dfrB2 gene fused to 
rrnB T1T2 terminators (ApR, TpR) 
This study 
pKNOCK-Km Mobilizable suicide vector containing 
aphA2 gene (KmR) 
(Alexeyev, 1999) 
p34E-Tp p34E containing dfrB2 gene (ApR, TpR) (DeShazer and Woods, 
1996) 
p34E-Km p34E containing aphA2 gene from 
pKNOCK-Km (ApR, KmR) 
This study 
p34E-Cm2 p34E containing catA2 gene from pSa with 
synthetic promoter (ApR, CmR) 
This study 
p34E-TpTer p34E containing dfrB2 gene fused to rrnB 
T1T2 terminators (ApR, TpR) 
This study 
31 
pBHR1-GFP pBHR1 containing gfp gene from pQBI-T7-
GFP (CmR, KmR) 
(Stevens et al., 2005) 
pSHAFT Suicide vector derived from pUTmini-
Tn5Cm containing deletion of BglII 
fragment harboring tnp gene and I end of 
mini-Tn5Cm, R6K-derived replicon, 
oriT+(ApR, CmR) 
(Shalom, 2002; Agnoli 
et al., 2006) 
pSHAFT-GFP pSHAFT with 3.7 kb :-Cm interposon 
replaced by gfp gene from pBHR1-GFP 
This study 
pSHAFT2 pSHAFT with 3.7 kb :-Cm region 
replaced by catA2 gene driven by 
synthetic promoter and additional unique 
UHVWULFWLRQVLWHVDW¶HQG$SR, CmR) 
This study 
pSHAFT3 pSHAFT2 derivative with deletion of two 
EcoRI sites, addition of ApaI and SpeI 
sites and removal of the mini-Tn5 O end 
(ApR, CmR) 
This study 
pBBR1-
%&$0¶ 
pBBR1MCS-1 containing B. cenocepacia 
H111 BCAM0195 gene fragment, lacking 
0.55 kbp at the ¶end (CmR) 
This study 
pBBR1-
%&$0¶7S 
pBBR1-%&$0¶ ZLWK dfrB2 gene 
replacing a 1.58 kb segment of 
%&$0¶&PR, TpR) 
This study 
pSHAFT2-
%&$0¶7S 
pSHAFT2 containing the XhoI-XbaI 
%&$0¶7S IUDJPHQW IURP S%%5-
%&$0¶7S$SR, CmR, TpR) 
This study 
pSHAFT-GFP-
BCAL1709 
pSHAFT-GFP containing B. cenocepacia 
Pc715j BCAL1709 gene (ApR, CmR) 
This study 
32 
pSHAFT-GFP-
BCAL1709::TpTer 
pSHAFT-GFP-BCAL1709 with dfrB2-rrnB 
T1T2 cassette inserted in BCAL1709 (ApR, 
CmR, TpR) 
This study 
 
Abbreviations: ApR, ampicillin-resistant; CmR, chloramphenicol-resistant; KmR, 
kanamycin-resistant; SmR, streptomycin-resistant; TcR, tetracycline-resistant; TpR, 
trimethoprim-resistant; BHR, broad host range. 
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Table S2. Primers used in this study 
Primer ID Primer sequencea,b 
 
p34E-Cmfor2 ¶-GCGCGAATTCTTGACAATTAAGCCCGTATATGGTATTATTA 
CTGAAT 
p34E-Cmrev ¶-GCGCGAATTCCCGGATACGGTGGCTTAAAT 
rrnBterfor 5'-CGCGGATCCAATTGAGAGTAGGGAACTGCCAGGCA 
rrnBterrev 5'-GCGCAAGCTTCTCGAGGGTACCGAGCTCGAATTCTTGTAG 
ATATGACGACAGGA 
Tp(forward) 5'-GCGGAATTCAGGCCTCATATGCACGAACCCAGTTGACAT 
Tp(reverse) 5'-CTGGCAGTTCCCTACTCTCTTAGGCCACACGTTCAAGTGC 
rrn(R) 5'-GACAAGCTTAGGCCTCATATGGTAGATATGACGACAGGAA 
GAG 
pSHOOTERfor2  ¶-GCGCGGATCCTTGACAATTAAGCCCGTATATGGTATTATT 
ACTGAAT 
pSHOOTERrev ¶-GCGCGTCGACAAAGATCTAATCTAGAAAGGTACCAACTCG 
AGAAAGGCCTAAGAGCTCCCGGATACGGTGGCTTAAAT 
pSHAFT3MCSfor  ¶-GGCCGCAAACTAGTAAGGGCCCAAG  
pSHAFT3MCSrev ¶-AATTCTTGGGCCCTTACTAGTTTGC  
GFPfor  ¶-GCGCGTCGACAACCCGGGAAAGATCTAATCTAGAAAGGTA 
CCAACTCGAGAAAGGCCTTTGACATTTGCAGATTCGCCTTC 
TATAAT AATTCGCCCTTCCCCTGTAGAAATAATTTTG 
GFPrev ¶-CTTTGTTAGCAGCCGGATCC 
BCAM0195for  ¶-GCGCAAGCTTATGAGCGGCCTGCTCGATCA 
BCAM0195rev ¶-GCGCGGATCCACGTCTTCACCACGCGGGTT  
BCAL1709for ¶-GCGCTCTAGAGCTGCTGCAGTTCGAATACG 
BCAL1709rev ¶-CGTCGCATTCGCGTAGTAGT 
BCAL1709forOut ¶-CGGAAAACTTCGGACATGTG 
34 
BCAL1709revOut ¶-GCGAGGTCAGAACTTGTATG 
aSequences specifying restriction endonuclease cleavage sites are underlined. 
bSequences corresponding to the -35 and -10 elements of the artificial promoters introduced 
upstream of the catA2 and gfp genes are enclosed in boxes. TKHIRUPHULVDQµH[WHQGHG¶-10 
promoter (Bown et al., 1997). 
 
 
